Shukra Pharmaceuticals Ltd () News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 505931,
    "name": "Shukra Pharma.",
    "stock_name": "Shukra Pharma.",
    "full_name": "Shukra Pharmaceuticals Ltd",
    "name_url": "stocks-analysis/shukra-pharma",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "44.57",
    "chg": 2.12,
    "chgp": "4.99%",
    "dir": 1,
    "prev_price": "42.45",
    "mcapval": "1,952.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 524632,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE551C01044",
    "curr_date": "Feb 09",
    "curr_time": "",
    "bse_nse_vol": "49.66 k",
    "exc_status": "Active",
    "traded_date": "Feb 09, 2026",
    "traded_date_str": "2026 02 09",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/shukra-pharma-505931-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Are Shukra Pharmaceuticals Ltd latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-shukra-pharmaceuticals-ltd-latest-results-good-or-bad-3822883",
        "imagepath": "",
        "date": "2026-02-05 19:24:26",
        "description": "Shukra Pharmaceuticals Ltd has reported significant financial results for the quarter ending December 2025, marking a notable turnaround from previous periods. The company achieved a net profit of ₹20.36 crores, reflecting a substantial increase of 755.46% compared to the previous quarter. Additionally, revenue surged to ₹39.13 crores, representing a remarkable growth of 565.48% quarter-on-quarter. This performance is underscored by an operating margin of 69.33%, which is the highest recorded in the company's history, and a PAT margin of 52.03%, indicating strong profitability metrics.\n\nThe latest results suggest a significant inflection point for Shukra Pharmaceuticals, which has faced challenges in maintaining consistent performance in prior quarters. The dramatic recovery in both revenue and profit is attributed to improved product realization and effective cost management, although the company has not d..."
      },
      {
        "title": "Are Shukra Pharmaceuticals Ltd latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-shukra-pharmaceuticals-ltd-latest-results-good-or-bad-3821028",
        "imagepath": "",
        "date": "2026-02-04 19:20:20",
        "description": "Shukra Pharmaceuticals Ltd's latest financial results for the quarter ending September 2025 present a complex picture of performance. The company reported a net profit of ₹2.38 crores, which marks a significant increase compared to the previous quarter's profit of ₹1.03 crores. This substantial growth in net profit is noteworthy, as it reflects a 131.07% increase quarter-on-quarter. However, this positive outcome is juxtaposed with a concerning operational trend, as the company recorded an operating loss of ₹0.42 crores, a stark contrast to the operating profit of ₹1.32 crores in the prior quarter. This resulted in a negative operating margin of -7.14%, indicating challenges in managing operational costs effectively.\n\nRevenue for the quarter was ₹5.88 crores, reflecting a modest growth of 9.09% from ₹5.39 crores in the previous quarter, but only a 5.76% increase year-on-year. The revenue growth, while posit..."
      },
      {
        "title": "Shukra Pharmaceuticals Q3 FY26: Explosive 565% Revenue Surge Masks Valuation Concerns",
        "link": "https://www.marketsmojo.com/news/result-analysis/shukra-pharmaceuticals-q3-fy26-explosive-565-revenue-surge-masks-valuation-concerns-3821116",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/ShukraPharmaceu_quaterlyResult_3821116.png",
        "date": "2026-02-04 19:16:18",
        "description": "Shukra Pharmaceuticals Ltd. delivered a dramatic turnaround in Q3 FY26, posting net profit of ₹20.36 crores—a staggering 755.46% surge from the previous quarter's ₹2.38 crores. The micro-cap pharmaceutical company, with a market capitalisation of ₹1,723 crores, reported revenues of ₹39.13 crores for the quarter ended December 2025, representing an extraordinary 565.48% sequential growth. However, the stock has retreated 1.84% to ₹38.88 following the results, reflecting investor caution over the company's stretched valuation multiples."
      },
      {
        "title": "Shukra Pharmaceuticals Ltd is Rated Hold",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/shukra-pharmaceuticals-ltd-is-rated-hold-3816215",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/ShukraPharmaceu_mojoScore_3816215.png",
        "date": "2026-02-02 10:10:47",
        "description": "Shukra Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, a rating that was last updated on 17 July 2025. While this rating change occurred several months ago, the analysis and financial metrics discussed here reflect the company’s current position as of 02 February 2026, providing investors with an up-to-date view of the stock’s fundamentals, valuation, financial trends, and technical outlook."
      },
      {
        "title": "When is the next results date for Shukra Pharmaceuticals Ltd?",
        "link": "https://www.marketsmojo.com/news/result-analysis/when-is-the-next-results-date-for-shukra-pharmaceuticals-ltd-3815049",
        "imagepath": "",
        "date": "2026-02-01 23:15:55",
        "description": "The next results date for Shukra Pharmaceuticals Ltd is scheduled for 04 February 2026...."
      },
      {
        "title": "Shukra Pharmaceuticals Ltd is Rated Hold",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/shukra-pharmaceuticals-ltd-is-rated-hold-3799868",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/ShukraPharmaceu_mojoScore_3799868.png",
        "date": "2026-01-22 10:10:41",
        "description": "Shukra Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, a rating that was last updated on 17 Jul 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 22 January 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook."
      },
      {
        "title": "Shukra Pharmaceuticals Ltd is Rated Hold",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/shukra-pharmaceuticals-ltd-is-rated-hold-3788791",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/ShukraPharmaceu_mojoScore_3788791.png",
        "date": "2026-01-11 10:10:27",
        "description": "Shukra Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, a rating that was last updated on 17 Jul 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 11 January 2026, providing investors with the latest insights into its performance and outlook."
      },
      {
        "title": "Shukra Pharmaceuticals Ltd Sees Mixed Technical Signals Amid Price Momentum Shift",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/shukra-pharmaceuticals-ltd-sees-mixed-technical-signals-amid-price-momentum-shift-3776967",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/ShukraPharmaceu_technicaldot_3776967.png",
        "date": "2026-01-01 08:03:46",
        "description": "Shukra Pharmaceuticals Ltd has experienced a notable shift in its technical momentum, with a recent downgrade in its Mojo Grade from Sell to Hold signalling a cautious optimism among investors. Despite a sharp 4.99% decline in the latest trading session, the stock’s long-term returns remain impressive, though mixed technical indicators suggest a complex near-term outlook."
      },
      {
        "title": "Shukra Pharmaceuticals Ltd is Rated Hold",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/shukra-pharmaceuticals-ltd-is-rated-hold-3776198",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/ShukraPharmaceu_mojoScore_3776198.png",
        "date": "2025-12-31 10:10:03",
        "description": "Shukra Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, a rating that was last updated on 17 Jul 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 31 December 2025, providing investors with an up-to-date perspective on the stock’s fundamentals, valuation, financial trends, and technical outlook."
      }
    ],
    "total": 613,
    "sid": "505931",
    "stock_news_url": "https://www.marketsmojo.com/news/shukra-pharmaceuticals-505931"
  },
  "announcements": [
    {
      "caption": "Newspaper Publication Of Standalone And Consolidated Un-Audited Financial Results For Quarter And Nine Month Ended 31St December 2025",
      "datetime": "05-Feb-2026",
      "details": "Newspaper publication of Standalone and Consolidated Un-audited Financial Results for Quarter and Nine month ended 31st December 2025",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Outcome for Outcome Of The Meeting Of Board Of Directors Held On Wednesday February 04 2026",
      "datetime": "04-Feb-2026",
      "details": "Considered and approved Un-audited Financial results of the Company for the Third Quarter and Nine Months ended December 31 2025.",
      "source": "BSE"
    },
    {
      "caption": "Unaudited Financial Results For The Quarter Ended December 2025",
      "datetime": "04-Feb-2026",
      "details": "Unaudited Financial Results for the quarter ended December 2025",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Shukra Pharmaceuticals Ltd has declared <strong>1%</strong> dividend, ex-date: 18 Sep 25",
          "dt": "2025-09-18",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "",
      "data": [
        {
          "txt": "Shukra Pharmaceuticals Ltd has announced <strong>1:10</strong> stock split, ex-date: 21 Mar 25",
          "dt": "2025-03-21",
          "middle_text": "Split"
        }
      ]
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "",
      "data": [
        {
          "txt": "Shukra Pharmaceuticals Ltd has announced <strong>3:1</strong> bonus issue, ex-date: 19 Apr 24",
          "dt": "2024-04-19",
          "middle_text": "Bonus Alert"
        }
      ]
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "",
      "data": [
        {
          "txt": "Shukra Pharmaceuticals Ltd has announced <strong>6:1</strong> rights issue, ex-date: 02 Feb 23",
          "dt": "2023-02-02",
          "middle_text": "Rights Issue"
        }
      ]
    }
  ]
}

News and Views

Are Shukra Pharmaceuticals Ltd latest results good or bad?

2026-02-05 19:24:26

Shukra Pharmaceuticals Ltd has reported significant financial results for the quarter ending December 2025, marking a notable turnaround from previous periods. The company achieved a net profit of ₹20.36 crores, reflecting a substantial increase of 755.46% compared to the previous quarter. Additionally, revenue surged to ₹39.13 crores, representing a remarkable growth of 565.48% quarter-on-quarter. This performance is underscored by an operating margin of 69.33%, which is the highest recorded in the company's history, and a PAT margin of 52.03%, indicating strong profitability metrics. The latest results suggest a significant inflection point for Shukra Pharmaceuticals, which has faced challenges in maintaining consistent performance in prior quarters. The dramatic recovery in both revenue and profit is attributed to improved product realization and effective cost management, although the company has not d...

Read full news article

Are Shukra Pharmaceuticals Ltd latest results good or bad?

2026-02-04 19:20:20

Shukra Pharmaceuticals Ltd's latest financial results for the quarter ending September 2025 present a complex picture of performance. The company reported a net profit of ₹2.38 crores, which marks a significant increase compared to the previous quarter's profit of ₹1.03 crores. This substantial growth in net profit is noteworthy, as it reflects a 131.07% increase quarter-on-quarter. However, this positive outcome is juxtaposed with a concerning operational trend, as the company recorded an operating loss of ₹0.42 crores, a stark contrast to the operating profit of ₹1.32 crores in the prior quarter. This resulted in a negative operating margin of -7.14%, indicating challenges in managing operational costs effectively. Revenue for the quarter was ₹5.88 crores, reflecting a modest growth of 9.09% from ₹5.39 crores in the previous quarter, but only a 5.76% increase year-on-year. The revenue growth, while posit...

Read full news article

Shukra Pharmaceuticals Q3 FY26: Explosive 565% Revenue Surge Masks Valuation Concerns

2026-02-04 19:16:18

Shukra Pharmaceuticals Ltd. delivered a dramatic turnaround in Q3 FY26, posting net profit of ₹20.36 crores—a staggering 755.46% surge from the previous quarter's ₹2.38 crores. The micro-cap pharmaceutical company, with a market capitalisation of ₹1,723 crores, reported revenues of ₹39.13 crores for the quarter ended December 2025, representing an extraordinary 565.48% sequential growth. However, the stock has retreated 1.84% to ₹38.88 following the results, reflecting investor caution over the company's stretched valuation multiples.

Read full news article

Shukra Pharmaceuticals Ltd is Rated Hold

2026-02-02 10:10:47

Shukra Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, a rating that was last updated on 17 July 2025. While this rating change occurred several months ago, the analysis and financial metrics discussed here reflect the company’s current position as of 02 February 2026, providing investors with an up-to-date view of the stock’s fundamentals, valuation, financial trends, and technical outlook.

Read full news article

When is the next results date for Shukra Pharmaceuticals Ltd?

2026-02-01 23:15:55

The next results date for Shukra Pharmaceuticals Ltd is scheduled for 04 February 2026....

Read full news article

Shukra Pharmaceuticals Ltd is Rated Hold

2026-01-22 10:10:41

Shukra Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, a rating that was last updated on 17 Jul 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 22 January 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook.

Read full news article

Shukra Pharmaceuticals Ltd is Rated Hold

2026-01-11 10:10:27

Shukra Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, a rating that was last updated on 17 Jul 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 11 January 2026, providing investors with the latest insights into its performance and outlook.

Read full news article

Shukra Pharmaceuticals Ltd Sees Mixed Technical Signals Amid Price Momentum Shift

2026-01-01 08:03:46

Shukra Pharmaceuticals Ltd has experienced a notable shift in its technical momentum, with a recent downgrade in its Mojo Grade from Sell to Hold signalling a cautious optimism among investors. Despite a sharp 4.99% decline in the latest trading session, the stock’s long-term returns remain impressive, though mixed technical indicators suggest a complex near-term outlook.

Read full news article

Shukra Pharmaceuticals Ltd is Rated Hold

2025-12-31 10:10:03

Shukra Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, a rating that was last updated on 17 Jul 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 31 December 2025, providing investors with an up-to-date perspective on the stock’s fundamentals, valuation, financial trends, and technical outlook.

Read full news article

View All News